Compared to pyrosequencing (including in-house methods, and the therascreen® KRAS Pyro Kit and RAS Extension Pyro Kit [Qiagen]), the cobas® KRAS Mutation Test (Roche), and NGS (Ion Torrent AmpliSeqTM Colon and Lung Cancer Research Panel [Life Technologies]), the observed concordances varied between 91.5% and 100% for these initial results. Here, KRAS is linked to lung carcinoma.